BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 27408796)

  • 1. Cortical thickness in relation to clinical symptom onset in preclinical AD.
    Pettigrew C; Soldan A; Zhu Y; Wang MC; Moghekar A; Brown T; Miller M; Albert M;
    Neuroimage Clin; 2016; 12():116-22. PubMed ID: 27408796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive reserve and cortical thickness in preclinical Alzheimer's disease.
    Pettigrew C; Soldan A; Zhu Y; Wang MC; Brown T; Miller M; Albert M;
    Brain Imaging Behav; 2017 Apr; 11(2):357-367. PubMed ID: 27544202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
    Wang ML; Wei XE; Yu MM; Li PY; Li WB;
    Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease.
    Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M;
    Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum.
    Marshall GA; Lorius N; Locascio JJ; Hyman BT; Rentz DM; Johnson KA; Sperling RA
    J Alzheimers Dis; 2014; 41(3):719-28. PubMed ID: 24685624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals.
    d'Oleire Uquillas F; Jacobs HIL; Hanseeuw B; Marshall GA; Properzi M; Schultz AP; LaPoint MR; Johnson KA; Sperling RA; Vannini P
    Neuroimage Clin; 2018; 17():388-396. PubMed ID: 29159051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
    Kim CM; Hwang J; Lee JM; Roh JH; Lee JH; Koh JY;
    Curr Alzheimer Res; 2015; 12(6):563-71. PubMed ID: 26027813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complexity analysis of cortical surface detects changes in future Alzheimer's disease converters.
    Ruiz de Miras J; Costumero V; Belloch V; Escudero J; Ávila C; Sepulcre J
    Hum Brain Mapp; 2017 Dec; 38(12):5905-5918. PubMed ID: 28856799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
    Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment.
    Auning E; Selnes P; Grambaite R; Šaltytė Benth J; Haram A; Løvli Stav A; Bjørnerud A; Hessen E; Hol PK; Muftuler løndalen A; Fladby T; Aarsland D
    Acta Psychiatr Scand; 2015 Feb; 131(2):139-47. PubMed ID: 25346330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased N-Acetyl Aspartate/Myo-Inositol Ratio in the Posterior Cingulate Cortex Shown by Magnetic Resonance Spectroscopy May Be One of the Risk Markers of Preclinical Alzheimer's Disease: A 7-Year Follow-Up Study.
    Waragai M; Moriya M; Nojo T
    J Alzheimers Dis; 2017; 60(4):1411-1427. PubMed ID: 28968236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortical signature of clock drawing performance in Alzheimer's disease and mild cognitive impairment.
    Hirjak D; Wolf RC; Pfeifer B; Kubera KM; Thomann AK; Seidl U; Maier-Hein KH; Schröder J; Thomann PA
    J Psychiatr Res; 2017 Jul; 90():133-142. PubMed ID: 28284155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations of whole-brain cortical area and thickness in mild cognitive impairment and Alzheimer's disease.
    Li C; Wang J; Gui L; Zheng J; Liu C; Du H
    J Alzheimers Dis; 2011; 27(2):281-90. PubMed ID: 21799248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.
    Kester MI; Teunissen CE; Sutphen C; Herries EM; Ladenson JH; Xiong C; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    Alzheimers Res Ther; 2015 Sep; 7(1):59. PubMed ID: 26383836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease.
    Vogel JW; Vachon-Presseau E; Pichet Binette A; Tam A; Orban P; La Joie R; Savard M; Picard C; Poirier J; Bellec P; Breitner JCS; Villeneuve S;
    Brain; 2018 Jun; 141(6):1871-1883. PubMed ID: 29688388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brainstem Volumetric Integrity in Preclinical and Prodromal Alzheimer's Disease.
    Dutt S; Li Y; Mather M; Nation DA;
    J Alzheimers Dis; 2020; 77(4):1579-1594. PubMed ID: 32925030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural volume and cortical thickness differences between males and females in cognitively normal, cognitively impaired and Alzheimer's dementia population.
    Sangha O; Ma D; Popuri K; Stocks J; Wang L; Beg MF; ;
    Neurobiol Aging; 2021 Oct; 106():1-11. PubMed ID: 34216846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.